Moreover, the availability of multiple effective obesity pharmacotherapies with different mechanisms of action will provide clinicians the opportunity to select treatments based on patient preference, underlying comorbidities, medication safety profile and treatment response, with an aim to achieve the individualised WL targets, improve the overall health and/or the quality of life [7]
The Glucagon-Like Peptide-1 Receptor Agonist Exendin-4 Inhibits Lipopolysaccharide-Induced Osteoclast Formation and Bone Resorption via Inhibition of TNF-alpha Expression in Macrophages
More evidence suggests that medications such as Ozempic and Mounjaro, originally developed for diabetes and then approved for obesity, have benefits that go beyond these conditions
The medication suppresses appetite through direct receptor activation, and when that activation stops, appetite returns, often stronger than baseline due to metabolic adaptation